Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATNM NASDAQ:CRGX NASDAQ:KRRO NASDAQ:LYEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.58-6.5%$1.63$1.03▼$2.41$49.29M-0.3400,341 shs390,884 shsCRGXCARGO Therapeutics$4.47$4.48$3.00▼$25.45$216.17M0.31.73 million shsN/AKRROKorro Bio$33.18+18.2%$17.18$10.29▼$98.00$311.59M2.66168,762 shs1.01 million shsLYELLyell Immunopharma$12.15+3.7%$10.67$7.65▼$32.00$233.41M-0.1926,417 shs18,409 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals0.00%-11.24%+1.28%-13.66%-12.22%CRGXCARGO Therapeutics0.00%0.00%-0.22%-5.89%-75.14%KRROKorro Bio0.00%+43.76%+109.21%+127.42%-21.76%LYELLyell Immunopharma0.00%+9.66%+7.33%-4.78%-55.98%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.58-6.5%$1.63$1.03▼$2.41$49.29M-0.3400,341 shs390,884 shsCRGXCARGO Therapeutics$4.47$4.48$3.00▼$25.45$216.17M0.31.73 million shsN/AKRROKorro Bio$33.18+18.2%$17.18$10.29▼$98.00$311.59M2.66168,762 shs1.01 million shsLYELLyell Immunopharma$12.15+3.7%$10.67$7.65▼$32.00$233.41M-0.1926,417 shs18,409 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals0.00%-11.24%+1.28%-13.66%-12.22%CRGXCARGO Therapeutics0.00%0.00%-0.22%-5.89%-75.14%KRROKorro Bio0.00%+43.76%+109.21%+127.42%-21.76%LYELLyell Immunopharma0.00%+9.66%+7.33%-4.78%-55.98%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNMActinium Pharmaceuticals 3.00Buy$4.50184.81% UpsideCRGXCARGO Therapeutics 1.86Reduce$15.40244.52% UpsideKRROKorro Bio 3.29Buy$86.83161.70% UpsideLYELLyell Immunopharma 1.50Reduce$15.0023.46% UpsideCurrent Analyst Ratings BreakdownLatest ATNM, KRRO, CRGX, and LYEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/13/2025KRROKorro BioRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetStrong-Buy$153.00 ➝ $147.008/13/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$100.00 ➝ $90.007/24/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.007/8/2025CRGXCARGO TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$3.70 ➝ $5.006/24/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.006/24/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$10.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNMActinium PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/ACRGXCARGO TherapeuticsN/AN/AN/AN/A$4.91 per shareN/AKRROKorro Bio$2.27M137.25N/AN/A$17.12 per share1.94LYELLyell Immunopharma$60K3,890.03N/AN/A$26.21 per share0.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNMActinium Pharmaceuticals-$48.82M-$1.31N/AN/AN/AN/A-100.85%-47.89%N/ACRGXCARGO Therapeutics-$167.50M-$4.64N/AN/AN/AN/A-43.21%-37.26%11/11/2025 (Estimated)KRROKorro Bio-$83.58M-$9.75N/AN/AN/AN/A-61.51%-42.87%11/11/2025 (Estimated)LYELLyell Immunopharma-$342.99M-$24.29N/AN/AN/A-552,328.31%-85.58%-68.85%11/6/2025 (Estimated)Latest ATNM, KRRO, CRGX, and LYEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025KRROKorro Bio-$2.54-$2.74-$0.20-$2.74$0.41 million$1.46 million8/12/2025Q2 2025LYELLyell Immunopharma-$3.80-$2.89+$0.91-$2.89$0.00 million$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNMActinium PharmaceuticalsN/AN/AN/AN/AN/ACRGXCARGO TherapeuticsN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/ALYELLyell ImmunopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNMActinium PharmaceuticalsN/A10.2510.25CRGXCARGO TherapeuticsN/A12.3712.37KRROKorro BioN/A5.985.98LYELLyell ImmunopharmaN/A7.657.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNMActinium Pharmaceuticals27.50%CRGXCARGO Therapeutics93.16%KRROKorro Bio13.18%LYELLyell Immunopharma66.05%Insider OwnershipCompanyInsider OwnershipATNMActinium Pharmaceuticals6.00%CRGXCARGO Therapeutics2.92%KRROKorro Bio4.60%LYELLyell Immunopharma22.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableCRGXCARGO Therapeutics11648.36 million46.95 millionN/AKRROKorro Bio709.39 million8.96 millionNo DataLYELLyell Immunopharma27019.21 million14.93 millionOptionableATNM, KRRO, CRGX, and LYEL HeadlinesRecent News About These CompaniesLyell Immunopharma Launches Phase III Trial of Dual-Targeted CAR T-Cell Therapy in Large B-Cell LymphomaSeptember 5 at 9:38 PM | precisionmedicineonline.comPLyell Immunopharma, Inc. $LYEL Shares Bought by Almitas Capital LLCSeptember 5 at 6:46 AM | marketbeat.comLyell Immunopharma Positioned for Potential Breakthrough with Aggressive Clinical StrategySeptember 5 at 4:13 AM | aktiencheck.deACharles Schwab Investment Management Inc. Reduces Holdings in Lyell Immunopharma, Inc. $LYELSeptember 4 at 3:06 AM | marketbeat.comLyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering ...September 3, 2025 | markets.businessinsider.comLyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering CommitteeSeptember 3, 2025 | globenewswire.comLyell Immunopharma Announces Participation in September Investor ConferencesSeptember 2, 2025 | globenewswire.comLyell Immunopharma (NASDAQ:LYEL) Raised to "Hold" at Wall Street ZenSeptember 2, 2025 | marketbeat.comLyell Immunopharma (NASDAQ:LYEL) Upgraded to Hold at Wall Street ZenSeptember 2, 2025 | americanbankingnews.comLyell Immunopharma (NASDAQ:LYEL) Cut to Strong Sell at Wall Street ZenAugust 17, 2025 | marketbeat.comLyell Immunopharma (NASDAQ:LYEL) Announces Quarterly Earnings ResultsAugust 14, 2025 | marketbeat.comLyell Immunopharma Advances CAR T-Cell TherapiesAugust 14, 2025 | msn.comLyell Immunopharma trading resumesAugust 13, 2025 | msn.comLyell Immunopharma trading halted, volatility trading pauseAugust 13, 2025 | msn.comLyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025August 13, 2025 | finanznachrichten.deLyell Immunopharma files to sell 3.75M shares of common stock for holdersAugust 13, 2025 | msn.comLyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025August 12, 2025 | globenewswire.comEquity Insider: Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer TreatmentsJuly 30, 2025 | finanznachrichten.deLyell Immunopharma (LYEL) Stock Soars Following Private Placement AnnouncementJuly 25, 2025 | financialbuzz.comFLyell Immunopharma Shares Rise After Private Placement of Up to $100MJuly 25, 2025 | marketwatch.comLyell Immunopharma Announces up to $100 Million Equity Private PlacementJuly 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATNM, KRRO, CRGX, and LYEL Company DescriptionsActinium Pharmaceuticals NYSE:ATNM$1.58 -0.11 (-6.51%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.55 -0.03 (-1.90%) As of 09/5/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.CARGO Therapeutics NASDAQ:CRGX$4.47 0.00 (0.00%) As of 08/19/2025CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.Korro Bio NASDAQ:KRRO$33.18 +5.10 (+18.16%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$33.12 -0.05 (-0.17%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Lyell Immunopharma NASDAQ:LYEL$12.15 +0.43 (+3.67%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$12.23 +0.08 (+0.66%) As of 09/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
